Features and advantages of aprecitentan (Tryvio)

Aprocitentan-Tryvio is a new oral antihypertensive drug that belongs to the dual endothelin receptor antagonist (ERA) class. Unlike common calcium channel blockers, ACE inhibitors, ARBs or diuretics, aprecitentan inhibits the effects of endothelin-1, a powerful vasoconstrictor, by selectively blocking endothelin A (ETA) and endothelin B (ETB) receptors. Endothelin-1 plays a key role in the development of many refractory hypertension, chronic kidney disease, and cardiovascular injury. Long-term vasoconstriction and remodeling will lead to a sustained increase in blood pressure, and aprecitentan reduces vascular tension from the source by blocking this pathway, so it plays an important role in the treatment of refractory hypertension.

Traditional antihypertensive drugs often target a certain pathway. For example, diuretics reduce blood volume by excreting sodium and diluting water. ACEI/ARB dilate blood vessels by interfering with the renin-angiotensin system. Aprecitentan makes up for the lack of efficacy of these drugs in some patients. According to overseas data, aprecitentan can further reduce blood pressure on the basis of combined with standard antihypertensive treatment, and has certain value for patients who have taken three or more antihypertensive drugs and still have no control. This makes it a high-profile innovative option in the field of “resistant hypertension.”

From a pharmacological perspective, aprecitentan's dual receptor antagonistic mechanism means that it can not only reduce the contraction of vascular smooth muscle, but also improve vascular endothelial function and partially alleviate the long-term vascular remodeling caused by endothelial damage. Compared with early monoreceptor antagonists, it lowers blood pressure while having a relatively controllable risk of side effects. For example, the incidence of peripheral edema may be lower than that of some older generation ERA drugs. This also makes its safety gradually recognized clinically.

In terms of indications, aprecitentan is not a first-line drug for general patients with mild to moderate hypertension, but is mainly targeted at refractory people who have insufficient response to conventional treatments. Its mechanism of action determines that it is more like a supplement and enhancement to existing antihypertensive programs rather than a replacement. Therefore, doctors usually make individual adjustments based on the patient's blood pressure control, comorbid diseases, and tolerance when making selections.

Looking at future trends, as the global population of hypertensive patients continues to grow, especially as there are more and more complex patients with metabolic syndrome, diabetes, and renal insufficiency, it is difficult for a single drug to meet all needs. Innovative targeted drugs such as aprecitentan may occupy a greater position in multi-drug combination treatments. At the same time, research continues on its potential benefits in chronic kidney disease and heart failure.

In summary, apremicitentan (Tryvio) belongs to the dual endothelin receptor antagonist class of antihypertensive drugs. It has a different mechanism of action from conventional antihypertensive drugs and is mainly used for the auxiliary treatment of refractory hypertension. It improves vasoconstriction and remodeling by targeting the endothelin-1 pathway, providing new treatment hope for some patients with long-term blood pressure substandard. It also represents the trend of antihypertensive drug research and development toward more precision and mechanism innovation.

Reference materials:https://go.drugbank.com/drugs/DB15059